IBDEI1YU ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,188,0)
 ;;=GENITOURINARY^9^21
 ;;^UTILITY(U,$J,358.4,189,0)
 ;;=HEMATOLOGY/ONCOLOGY^10^21
 ;;^UTILITY(U,$J,358.4,190,0)
 ;;=INJURY/TRAUMA^11^21
 ;;^UTILITY(U,$J,358.4,191,0)
 ;;=SIGNS, SYMPTOMS, CONDITIONS^21^21
 ;;^UTILITY(U,$J,358.4,192,0)
 ;;=PAIN^17^21
 ;;^UTILITY(U,$J,358.4,193,0)
 ;;=COMPLICATIONS^4^21
 ;;^UTILITY(U,$J,358.4,194,0)
 ;;=CONTACT W/ HAZARDOUS SUBSTANCES^5^21
 ;;^UTILITY(U,$J,358.4,195,0)
 ;;=V CODES^22^21
 ;;^UTILITY(U,$J,358.4,196,0)
 ;;=MASS^13^21
 ;;^UTILITY(U,$J,358.4,197,0)
 ;;=SCI^20^21
 ;;^UTILITY(U,$J,358.4,198,0)
 ;;=ALZHEIMERS^1^21
 ;;^UTILITY(U,$J,358.4,199,0)
 ;;=MEDICAL^14^21
 ;;^UTILITY(U,$J,358.4,200,0)
 ;;=PSYCHIATRIC^18^21
 ;;^UTILITY(U,$J,358.4,201,0)
 ;;=ENDOCRINE/METOBOLIC^6^21
 ;;^UTILITY(U,$J,358.4,202,0)
 ;;=ENT^7^21
 ;;^UTILITY(U,$J,358.4,203,0)
 ;;=BLINDNESS^2^21
 ;;^UTILITY(U,$J,358.4,204,0)
 ;;=LATE EFFECT STROKE^12^21
 ;;^UTILITY(U,$J,358.4,205,0)
 ;;=OTHER^3^22
 ;;^UTILITY(U,$J,358.4,206,0)
 ;;=COMMONLY USED CODES^1^22
 ;;^UTILITY(U,$J,358.4,207,0)
 ;;=WARFARIN CLINIC CODES^2^22
 ;;^UTILITY(U,$J,358.4,208,0)
 ;;=NEW PATIENT^1^23
 ;;^UTILITY(U,$J,358.4,209,0)
 ;;=ESTABLISHED PATIENT^2^23
 ;;^UTILITY(U,$J,358.4,210,0)
 ;;=EDUCATION & TRAINING FOR SELF MGMT^3^23
 ;;^UTILITY(U,$J,358.4,211,0)
 ;;=NEW PATIENT^2^24
 ;;^UTILITY(U,$J,358.4,212,0)
 ;;=ESTABLISHED PATIENT^1^24
 ;;^UTILITY(U,$J,358.4,213,0)
 ;;=CONSULTATIONS^3^24
 ;;^UTILITY(U,$J,358.4,214,0)
 ;;=BIOPSY/DEBRIDEMENT^1^25
 ;;^UTILITY(U,$J,358.4,215,0)
 ;;=I&D/ASPIRATION^10^25
 ;;^UTILITY(U,$J,358.4,216,0)
 ;;=DESTRUCT-BENIGN/PREMALIG LESIONS^3^25
 ;;^UTILITY(U,$J,358.4,217,0)
 ;;=PARING/CUTTING^16^25
 ;;^UTILITY(U,$J,358.4,218,0)
 ;;=EXCISE BENIGN-SCALP/NECK/HAND/GENITAL/FT^5^25
 ;;^UTILITY(U,$J,358.4,219,0)
 ;;=EXCISE BENIGN-FACE/EAR/NOSE/LIP/LID^4^25
 ;;^UTILITY(U,$J,358.4,220,0)
 ;;=EXCISION BENIGN-TRUNK/ARM/LEG^6^25
 ;;^UTILITY(U,$J,358.4,221,0)
 ;;=EXCISE MALIG-FACE/EAR/NOSE/LIP/LID^7^25
 ;;^UTILITY(U,$J,358.4,222,0)
 ;;=EXCISE MALIG-SCALP/NECK/HAND/GENITAL/FT^8^25
 ;;^UTILITY(U,$J,358.4,223,0)
 ;;=EXCISION MALIG-TRUNK/ARM/LEG^9^25
 ;;^UTILITY(U,$J,358.4,224,0)
 ;;=REPAIR,SIMPLE-SCALP/NECK/TRUNK/EXTREM^21^25
 ;;^UTILITY(U,$J,358.4,225,0)
 ;;=REPAIR,SIMPLE-FACE/EAR/NOSE/LID/LIP^20^25
 ;;^UTILITY(U,$J,358.4,226,0)
 ;;=REPAIR,INTERMED-SCALP/TRUNK/LEG/ARM^19^25
 ;;^UTILITY(U,$J,358.4,227,0)
 ;;=REPAIR,INTERMED-FACE/EAR/NOSE/LID/LIP^17^25
 ;;^UTILITY(U,$J,358.4,228,0)
 ;;=REPAIR,INTERMED-NECK/HAND/GENITAL/FT^18^25
 ;;^UTILITY(U,$J,358.4,229,0)
 ;;=REPAIR-SIMPLE WOUND DEHISCENCE^22^25
 ;;^UTILITY(U,$J,358.4,230,0)
 ;;=NURSING PROCEDURES^14^25
 ;;^UTILITY(U,$J,358.4,231,0)
 ;;=BLOOD^2^25
 ;;^UTILITY(U,$J,358.4,232,0)
 ;;=IV INFUSION^11^25
 ;;^UTILITY(U,$J,358.4,233,0)
 ;;=MEDICATION^12^25
 ;;^UTILITY(U,$J,358.4,234,0)
 ;;=MEDICATION ADMINISTATION^13^25
 ;;^UTILITY(U,$J,358.4,235,0)
 ;;=PARACENTESIS^15^25
 ;;^UTILITY(U,$J,358.4,236,0)
 ;;=OTHER^23^25
 ;;^UTILITY(U,$J,358.4,237,0)
 ;;=POST-OP COMPLICATIONS^17^26
 ;;^UTILITY(U,$J,358.4,238,0)
 ;;=GENERAL/SIGNS & SYMPTOMS^6^26
 ;;^UTILITY(U,$J,358.4,239,0)
 ;;=GYN/BREAST^8^26
 ;;^UTILITY(U,$J,358.4,240,0)
 ;;=MALE BREAST^10^26
 ;;^UTILITY(U,$J,358.4,241,0)
 ;;=BENIGN LESIONS OF SKIN^3^26
 ;;^UTILITY(U,$J,358.4,242,0)
 ;;=MALIGNANT LESIONS OF SKIN^11^26
 ;;^UTILITY(U,$J,358.4,243,0)
 ;;=MELANOMA^12^26
 ;;^UTILITY(U,$J,358.4,244,0)
 ;;=LACERATIONS^9^26
 ;;^UTILITY(U,$J,358.4,245,0)
 ;;=MERKEL CELL CANCER^13^26
 ;;^UTILITY(U,$J,358.4,246,0)
 ;;=AFTERCARE POST SURGERY^2^26
 ;;^UTILITY(U,$J,358.4,247,0)
 ;;=CARDIOVASCULAR^4^26
 ;;^UTILITY(U,$J,358.4,248,0)
 ;;=ENT^5^26
